Advertisement
Screener

CORCEPT THERAPEUTICS INC (CORT) Increase (Decrease) in Other Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

CORCEPT THERAPEUTICS INC Increase (Decrease) in Other Accrued Liabilities

CORCEPT THERAPEUTICS INC (CORT) reported Increase (Decrease) in Other Accrued Liabilities of $24.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2026-07-29

  • CORCEPT THERAPEUTICS INC increase (decrease) in other accrued liabilities for the quarter ending 2026-06-30 was $34.31M, a 380.67% increase year-over-year.
  • CORCEPT THERAPEUTICS INC increase (decrease) in other accrued liabilities for the quarter ending 2026-03-31 was -$9.38M.
  • CORCEPT THERAPEUTICS INC increase (decrease) in other accrued liabilities for the quarter ending 2025-12-31 was -$13.24M, a 223.57% decline year-over-year.
  • CORCEPT THERAPEUTICS INC increase (decrease) in other accrued liabilities for the quarter ending 2025-09-30 was $15.90M, a 19.00% decline year-over-year.
  • CORCEPT THERAPEUTICS INC increase (decrease) in other accrued liabilities for fiscal 2025 was $3.93M, a 89.73% decline from fiscal 2024.
  • CORCEPT THERAPEUTICS INC increase (decrease) in other accrued liabilities for fiscal 2024 was $38.24M, a 116.68% increase from fiscal 2023.
  • CORCEPT THERAPEUTICS INC increase (decrease) in other accrued liabilities for fiscal 2023 was $17.65M, a 502.97% increase from fiscal 2022.
  • CORCEPT THERAPEUTICS INC increase (decrease) in other accrued liabilities for fiscal 2022 was $2.93M, a 54.82% decline from fiscal 2021.
Period endIncrease (Decrease) in Other Accrued Liabilities 3 monthIncrease (Decrease) in Other Accrued Liabilities 3 month as first filedIncrease (Decrease) in Other Accrued Liabilities 6 monthIncrease (Decrease) in Other Accrued Liabilities 6 month as first filedIncrease (Decrease) in Other Accrued Liabilities 9 monthIncrease (Decrease) in Other Accrued Liabilities 9 month as first filedIncrease (Decrease) in Other Accrued Liabilities 12 month
2026-06-30$34.31M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
$24.94M
10-Q · filed 2026-07-29
$11.70M
derived: sum of 3 quarters · filed 2026-07-29
$27.60M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31-$9.38M
10-Q · filed 2026-04-30
-$22.61M
derived: sum of 2 quarters · filed 2026-04-30
-$6.72M
derived: sum of 3 quarters · filed 2026-04-30
$422.00K
derived: sum of 4 quarters · filed 2026-07-29
2025-12-31-$13.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$2.66M
derived: sum of 2 quarters · filed 2026-02-24
$9.80M
derived: sum of 3 quarters · filed 2026-07-29
$3.93M
10-K · filed 2026-02-24
2025-09-30$15.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$23.04M
derived: sum of 2 quarters · filed 2026-07-29
$17.16M
10-Q · filed 2025-11-04
$27.88M
derived: sum of 4 quarters · filed 2026-07-29
2025-06-30$7.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
$1.27M
10-Q · filed 2026-07-29
$6.00K
10-Q · filed 2025-07-31
$11.98M
derived: sum of 3 quarters · filed 2026-07-29
$31.60M
derived: sum of 4 quarters · filed 2026-07-29
2025-03-31-$5.87M
10-Q · filed 2026-04-30
-$5.94M
10-Q · filed 2025-05-05
$4.84M
derived: sum of 2 quarters · filed 2026-04-30
$24.46M
derived: sum of 3 quarters · filed 2026-04-30
$23.26M
derived: sum of 4 quarters · filed 2026-04-30
2024-12-31$10.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$30.34M
derived: sum of 2 quarters · filed 2026-02-24
$29.13M
derived: sum of 3 quarters · filed 2026-02-24
$38.24M
10-K · filed 2026-02-24
2024-09-30$19.62M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$18.42M
derived: sum of 2 quarters · filed 2025-11-04
$27.53M
10-Q · filed 2025-11-04
$8.48M
derived: sum of 4 quarters · filed 2026-02-24
2024-06-30-$1.21M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31
$7.91M
10-Q · filed 2025-07-31
-$11.14M
derived: sum of 3 quarters · filed 2026-02-24
$6.28M
derived: sum of 4 quarters · filed 2026-02-24
2024-03-31$9.11M
10-Q · filed 2025-05-05
-$9.93M
derived: sum of 2 quarters · filed 2026-02-24
$7.48M
derived: sum of 3 quarters · filed 2026-02-24
$18.74M
derived: sum of 4 quarters · filed 2026-02-24
2023-12-31-$19.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$1.63M
derived: sum of 2 quarters · filed 2026-02-24
$9.62M
derived: sum of 3 quarters · filed 2026-02-24
$17.65M
10-K · filed 2026-02-24
2023-09-30$17.42M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30
$28.67M
derived: sum of 2 quarters · filed 2024-10-30
$36.70M
10-Q · filed 2024-10-30
$37.88M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$11.25M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-29
$19.28M
10-Q · filed 2024-07-29
$20.46M
derived: sum of 3 quarters · filed 2025-02-26
$25.13M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$8.03M
10-Q · filed 2024-05-01
$9.21M
derived: sum of 2 quarters · filed 2025-02-26
$13.88M
derived: sum of 3 quarters · filed 2025-02-26
$5.96M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31$1.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$5.85M
derived: sum of 2 quarters · filed 2025-02-26
-$2.07M
derived: sum of 3 quarters · filed 2025-02-26
$2.93M
10-K · filed 2025-02-26
2022-09-30$4.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01
-$3.25M
derived: sum of 2 quarters · filed 2023-11-01
$1.75M
10-Q · filed 2023-11-01
$5.10M
derived: sum of 4 quarters · filed 2024-02-15
2022-06-30-$7.92M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02
-$2.92M
10-Q · filed 2023-08-02
$435.00K
derived: sum of 3 quarters · filed 2024-02-15
$3.23M
derived: sum of 4 quarters · filed 2024-02-15
2022-03-31$5.00M
10-Q · filed 2023-05-03
$8.35M
derived: sum of 2 quarters · filed 2024-02-15
$11.15M
derived: sum of 3 quarters · filed 2024-02-15
$14.69M
derived: sum of 4 quarters · filed 2024-02-15
2021-12-31$3.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15
$6.15M
derived: sum of 2 quarters · filed 2024-02-15
$9.70M
derived: sum of 3 quarters · filed 2024-02-15
$6.48M
10-K · filed 2024-02-15
2021-09-30$2.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$6.34M
derived: sum of 2 quarters · filed 2022-11-03
$3.12M
10-Q · filed 2022-11-03
$3.14M
10-Q · filed 2021-11-03
$5.36M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30$3.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
$328.00K
10-Q · filed 2022-08-04
$333.00K
10-Q · filed 2021-07-29
$2.56M
derived: sum of 3 quarters · filed 2023-02-28
-$1.13M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31-$3.22M
10-Q · filed 2022-05-05
-$985.00K
derived: sum of 2 quarters · filed 2023-02-28
-$4.67M
derived: sum of 3 quarters · filed 2023-02-28
-$1.62M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31$2.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$1.46M
derived: sum of 2 quarters · filed 2023-02-28
$1.59M
derived: sum of 3 quarters · filed 2023-02-28
-$2.08M
10-K · filed 2023-02-28
2020-09-30-$3.69M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
-$639.00K
derived: sum of 2 quarters · filed 2021-11-03
-$4.32M
10-Q · filed 2021-11-03
-$2.63M
derived: sum of 4 quarters · filed 2022-02-15
2020-06-30$3.05M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29
-$628.00K
10-Q · filed 2021-07-29
$1.06M
derived: sum of 3 quarters · filed 2022-02-15
$6.20M
derived: sum of 4 quarters · filed 2022-02-15
2020-03-31-$3.68M
10-Q · filed 2021-05-06
-$1.99M
derived: sum of 2 quarters · filed 2022-02-15
$3.16M
derived: sum of 3 quarters · filed 2022-02-15
$763.00K
derived: sum of 4 quarters · filed 2022-02-15
2019-12-31$1.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15
$6.83M
derived: sum of 2 quarters · filed 2022-02-15
$4.44M
derived: sum of 3 quarters · filed 2022-02-15
-$517.00K
10-K · filed 2022-02-15
2019-09-30$5.14M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03
$2.75M
derived: sum of 2 quarters · filed 2020-11-03
-$2.21M
10-Q · filed 2020-11-03
$688.00K
derived: sum of 4 quarters · filed 2021-02-23
2019-06-30-$2.39M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04
-$7.35M
10-Q · filed 2020-08-04
-$4.45M
derived: sum of 3 quarters · filed 2021-02-23
-$2.67M
derived: sum of 4 quarters · filed 2021-02-23
2019-03-31-$4.96M
10-Q · filed 2020-05-04
-$2.06M
derived: sum of 2 quarters · filed 2021-02-23
-$282.00K
derived: sum of 3 quarters · filed 2021-02-23
$2.47M
derived: sum of 4 quarters · filed 2021-02-23
2018-12-31$2.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23
$4.67M
derived: sum of 2 quarters · filed 2021-02-23
$7.43M
derived: sum of 3 quarters · filed 2021-02-23
$5.04M
10-K · filed 2021-02-23
2018-09-30$1.78M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
$4.53M
derived: sum of 2 quarters · filed 2019-11-07
$2.15M
10-Q · filed 2019-11-07
$3.40M
derived: sum of 4 quarters · filed 2020-02-24
2018-06-30$2.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01
$370.00K
10-Q · filed 2019-08-01
$1.62M
derived: sum of 3 quarters · filed 2020-02-24
$5.64M
derived: sum of 4 quarters · filed 2020-02-24
2018-03-31-$2.38M
10-Q · filed 2019-05-09
-$1.14M
derived: sum of 2 quarters · filed 2020-02-24
$2.89M
derived: sum of 3 quarters · filed 2020-02-24
$5.18M
derived: sum of 4 quarters · filed 2020-02-24
2017-12-31$1.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24
$5.27M
derived: sum of 2 quarters · filed 2020-02-24
$7.56M
derived: sum of 3 quarters · filed 2020-02-24
$8.55M
10-K · filed 2020-02-24
2017-09-30$4.03M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02
$6.31M
derived: sum of 2 quarters · filed 2018-11-02
$7.30M
10-Q · filed 2018-11-02
$9.38M
derived: sum of 4 quarters · filed 2019-02-26
2017-06-30$2.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
$3.27M
10-Q · filed 2018-08-09
$5.35M
derived: sum of 3 quarters · filed 2019-02-26
$6.39M
derived: sum of 4 quarters · filed 2019-02-26
2017-03-31$985.00K
10-Q · filed 2018-05-09
$3.06M
derived: sum of 2 quarters · filed 2019-02-26
$4.11M
derived: sum of 3 quarters · filed 2019-02-26
$5.41M
derived: sum of 4 quarters · filed 2019-02-26
2016-12-31$2.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26
$3.12M
derived: sum of 2 quarters · filed 2019-02-26
$4.43M
derived: sum of 3 quarters · filed 2019-02-26
$5.70M
10-K · filed 2019-02-26
2016-09-30$1.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03
$2.35M
derived: sum of 2 quarters · filed 2017-11-03
$3.62M
10-Q · filed 2017-11-03
$4.04M
derived: sum of 4 quarters · filed 2018-02-28
2016-06-30$1.31M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02
$2.58M
10-Q · filed 2017-08-02
$3.00M
derived: sum of 3 quarters · filed 2018-02-28
$3.33M
derived: sum of 4 quarters · filed 2018-02-28
2016-03-31$1.27M
10-Q · filed 2017-05-02
$1.70M
derived: sum of 2 quarters · filed 2018-02-28
$2.02M
derived: sum of 3 quarters · filed 2018-02-28
$2.11M
derived: sum of 4 quarters · filed 2018-02-28
2015-12-31$425.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28
$750.00K
derived: sum of 2 quarters · filed 2018-02-28
$838.00K
derived: sum of 3 quarters · filed 2018-02-28
$1.38M
10-K · filed 2018-02-28
2015-09-30$325.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02
$413.00K
derived: sum of 2 quarters · filed 2016-11-02
$956.00K
10-Q · filed 2016-11-02
2015-06-30$88.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03
$631.00K
10-Q · filed 2016-08-03
2015-03-31$543.00K
10-Q · filed 2016-05-04
2014-12-31$575.00K
10-K · filed 2017-03-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52